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Abstract: Tight glycemic control is important in reducing and delaying vascular complications 
in type 1 and 2 diabetes patients; however, the benefits achieved through strict metabolic control 
are counterbalanced by an increased risk of hypoglycemia. Glucagon is an effective therapy 
for treating severe hypoglycemia. Available as an emergency kit, glucagon is an essential tool 
for rapid response, but remains underappreciated and underused. This article reviews the role 
of glucagon in treating severe hypoglycemia and discusses the need for better education on 
  glucagon for people with diabetes and their caregivers in order to alleviate fears of hypoglycemia 
and of administering glucagon in the event of an emergency.
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Introduction
It is well documented that tight glycemic control improves vascular complications in 
people with type 1 and type 2 diabetes. Seminal studies, including the Diabetes Control 
and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study 
(UKPDS), conclusively support the implementation of strict glycemic thresholds to 
delay progression of diabetes complications.1–6 However, the benefits conferred by 
strict metabolic control are counterbalanced by the increased risk of hypoglycemia 
that is an inevitable side effect of intensive insulin therapy.6
Hypoglycemia is associated with significant morbidity: physical (such as 
palpitations, sweating, and neurological impairments) as well as psychological (such 
as mood disturbance and generalized worry and fear of hypoglycemia);7–9 reductions 
in quality of life; and risk of death,9 with 2%–6% of all deaths in people with type 1 
  diabetes being attributed to hypoglycemia.10,11 Similarly, in patients with type 2   diabetes 
receiving sulfonylurea monotherapy, severe hypoglycemia has been associated with 
an overall mortality rate of 9%.12 In the Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) study, the use of intensive therapy for 3.7 years to target a 
glycated hemoglobin (HbA1c) level below 6% reduced 5-year nonfatal myocardial 
infarctions but increased 5-year mortality, leading the author to conclude that this 
treatment strategy should not be recommended for high-risk patients with advanced 
type 2 diabetes.13 The fear of future hypoglycemia events is often the underlying 
source of inappropriate management of diabetes and suboptimal glycemic control.14 
Self-management and regular monitoring of blood glucose levels are invaluable 
tools that aid the recognition of the signs and symptoms of hypoglycemia, therefore 
reducing the risk of hypoglycemia. While the implementation of continuous glucose Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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monitoring systems holds promise in children and adults for 
maintaining glycemic thresholds without a concurrent risk 
of hypoglycemia,15,16 studies have reported discrepancies 
between readings of continuous glucose monitors and blood 
glucose levels.17,18 Moreover, analysis of continuous glucose 
data is challenging and no method has yet been devised 
to overcome the issues associated with measuring such 
data.18 Therefore, there remains a need for precautionary 
measures to manage severe hypoglycemia events when 
they do occur.
The purpose of this review paper is to discuss causes 
and management of hypoglycemia with an emphasis on 
glucagon, which is the only first-line treatment for severe 
hypoglycemia that can be administered in a nonmedical 
environment.   Reasons for the underuse of glucagon are also 
discussed.19
Medline searches were conducted using combinations 
of the search terms diabetes, hypoglycemia, glucagon, 
  GlucGen® Hypokit® and The Glucagon Emergency Kit and 
articles were selected for relevance to the review paper. The 
reference sections of the selected publications were also 
searched for further relevant publications. Manufacturer/
product websites were viewed and Google searches 
  conducted using the above search terms to attain further 
information on glucagon kits.
Defining hypoglycemia
There is currently a lack of consensus regarding the 
  threshold blood glucose levels that classify different stages of 
  hypoglycemia. Existing thresholds for defining hypoglycemia 
are based on observations from clinical trial settings and 
may not be applicable to everyday practice.2 Variations in 
blood glucose threshold levels across different individu-
als also contribute to the failure to reach agreement on a 
universal clinical definition of hypoglycemia. For example, 
symptoms of hypoglycemia are likely to occur at higher 
levels of blood glucose in people who are poor at control-
ling their blood glucose levels than in people who tightly 
control their diabetes.9,20 Moreover, younger patients and 
those who have had diabetes for a short time are likely to 
detect an episode of hypoglycemia at higher plasma glucose 
levels.9,20 Notwithstanding individual considerations, there 
are general guidelines that define an episode of hypoglycemia 
as being mild (minor)-to-moderate or severe, dependent upon 
the patient’s ability to treat himself/herself.
Mild (minor)-to-moderate hypoglycemia is defined as: 
a hypoglycemia event that can be self-treated irrespective 
of symptom severity, or an asymptomatic blood glucose 
measurement of #3.9 mmol/L.2,8,21 Severe hypoglycemia 
is defined as: a hypoglycemia event that requires external 
(third-party) assistance.21 Notably, younger children will 
almost always need to be treated by a parent or caregiver when 
experiencing hypoglycemia; they may also have   difficulty 
explaining their symptoms verbally so it is   necessary for 
parents or caregivers to monitor behavior closely in order 
to detect possible hypoglycemia. According to the Interna-
tional Society of Pediatric and Adolescent Diabetes (ISPAD) 
guidelines of 2006–2007, severe hypoglycemia is when the 
child has “altered mental status and cannot assist in their care, 
is semiconscious or unconscious, or in coma with or without 
convulsions and may require parenteral therapy (glucagon or 
intravenous [IV] glucose)”.22
Reported estimates suggest a high incidence of hypo-
glycemia among adults and children with type 1 diabetes, 
with two symptomatic hypoglycemic episodes per week 
and episodes of severe hypoglycemia approximating to 11.5 
per 100 patient-years or 0.21 to 1.6 per patient per year 
(Figure 1).9,21,23–25 Hypoglycemia is less common, but still 
important, in type 2 diabetes; the incidence is approximately 
10%–20% of the observed rate in people with type 1 
diabetes.21,23–25 However, comparable with estimates for type 
1 diabetes, severe hypoglycemic episodes in patients with 
type 2 diabetes treated with insulin have been reported to be 
as high as 11.8 per 100 patient-years.23
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Figure 1 Distribution of self-reported number of episodes of severe hypoglycemia 
during the preceding year in 1049 unselected subjects with type 1 diabetes (light 
bars)  and  209  patients  with  type  1  diabetes  selected  by  criteria  to  mimic  the 
characteristics of the DCCT cohort (dark bars).
Reprinted from Diabetes Metab Res Rev, 20, U Pedersen-Bjergaard, S Pramming, SR 
Heller,  et  al,  Severe  hypoglycaemia  in  1076  adult  patients  with  type  1  diabetes: 
influence of risk markers and selection, 479–486, copyright (2004), with permission 
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What are the causes and symptoms 
of hypoglycemia?
Causes
The most frequently attributed cause of hypoglycemia is 
treatment with insulin or sulfonylureas (iatrogenic hypo-
glycemia), but additional underlying causes of nondiabetic 
hypoglycemia include pancreatic or nonislet cell tumors, 
autoimmune conditions (for example, autoimmune insulin 
syndrome), organ failure, endocrine disease, inborn errors 
of metabolism, dietary toxins, and miscellaneous conditions 
(such as sepsis, starvation, severe excessive exercise).26 
Table 1 lists several causes of hypoglycemia for people 
with diabetes.27 Among these possible causes, a recent study 
investigating the management of severe hypoglycemia in 
type 1 or insulin-treated type 2 diabetes in Germany, Spain 
and the UK, found that insufficient food consumption 
was the most common cause (43% or 47% of type 1 or 
2 patients with diabetes in all countries, respectively; 
  Figure 2) followed by physical exercise/over-exertion 
(24% or 23%), and insulin dose miscalculation (24% of 
type 1 diabetes patients) or stressful situations (17% of 
type 2 diabetes patients).28 The frequencies of these major 
causes of hypoglycemia in the type 1 and 2 diabetes patient 
groups were similar between countries. However, a notably 
greater proportion of German patients with type 1 diabetes 
(and, to a lesser extent, patients with type 2 diabetes from 
Germany) reported stressful situations, oscillating blood 
glucose levels, and impaired hypoglycemia awareness as a 
cause of hypoglycemia than patients in Spain and the UK 
(Figure 2).
Risks
A number of factors increase the risk of severe hypoglycemia 
in insulin-treated people with diabetes. Impaired awareness 
of hypoglycemia is a major risk factor, those with impaired 
awareness being up to nine times more likely to have a severe 
hypoglycemic episode than those with normal awareness.29–31 
Approximately 25% of patients with type 1 diabetes have 
impaired hypoglycemia awareness, with a lower incidence 
in those with type 2 diabetes.31–33 Such unawareness means 
there is an inability to detect the onset of hypoglycemia, 
and consequently, the individual is less likely to start 
corrective action sooner and more likely to go on to suffer 
severe episodes. Young age is also a risk factor for severe 
hypoglycemia due to lower awareness of the signs and 
symptoms,8,34 and the elderly also have less awareness of the 
signs and symptoms of hypoglycemia as a result of the aging 
process.23 Avoidance of severe hypoglycemia is particularly 
challenging in children and adolescents with diabetes since 
parents usually bear the responsibility for decisions on food 
intake, adjustment of insulin dosage, and appropriate man-
agement of exercise.8 A long duration of the disease2,23,35 
and previous experiences of severe hypoglycemia2,24 are 
additional risk factors for severe hypoglycemia.
Symptoms
Signs and symptoms of the onset of hypoglycemia are 
typified by autonomic symptoms such as tremor, hunger, 
sweating and palpitations (acting as early warnings to 
the patient of an impending episode) and nonspecific 
symptoms such as headache and nausea (Figure 3).36–38 
Symptoms of hypoglycemia may become progressively 
less intense over time or even diminish altogether, resulting 
in impaired awareness of hypoglycemia in a significant 
proportion of people (25%).39 Of the 201 patients whose 
awareness of hypoglycemia was questioned in a recent 
survey, 68% had normal awareness. Those patients 
needing health care treatment for severe hypoglycemia in 
this study often had impaired awareness and developed 
hypoglycemic coma more frequently.28 Children may be more 
vulnerable to hypoglycemia than adults, with observations 
of frequent failures among children and their parents to 
accurately recognize the early signs and symptoms of 
hypoglycemia.40
Pathophysiology
In diabetes, hypoglycemia arises from the combination of 
relative or absolute insulin excess and impaired physiological 
Table 1 Causes of hypoglycemia
Cause Example
incorrect insulin administration insulin taken in excess or at the  
wrong time relative to food intake   
and/or physical activity; incorrect  
type of insulin taken
Insufficient exogenous  
carbohydrate
Delayed or missed meals or 
overnight fast
Decreased endogenous 
glucose production
excess alcohol consumption
increased utilization of  
carbohydrate/depletion of  
hepatic glycogen stores
exercise or weight loss
increased insulin sensitivity During the night, exercise,  
weight loss
Delayed gastric emptying Conditions such as gastroparesis
Decreased insulin clearance Conditions such as progressive  
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defenses against the fall in plasma glucose.41 Glucose counter-
regulation, the physiological defense mechanism that prevents 
or restores balance in the event of hypoglycemia, is impaired 
in patients with type 1 diabetes and those with advanced type 
2 diabetes. Thus, compromised glucose counter-regulatory 
responses to hypoglycemia in the presence of an endogenous 
insulin-deficient state will manifest as a failure to decrease 
insulin levels and to increase glucagon levels accompanied by 
the attenuation of increased epinephrine levels. The blunting 
of autonomic (adrenomedullary and sympathetic neural) 
response is attributed to the observed clinical presentation 
of hypoglycemia unawareness. Furthermore, it is postulated 
that the reduced sympathoadrenal response (the concept 
of hypoglycemia-associated autonomic failure) is induced 
by recent antecedent hypoglycemia, resulting in defective 
  glucose counter-regulation and hypoglycemia unawareness 
that presents as recurrent cycles of hypoglycemia.9
Burden of hypoglycemia
Patient
The adverse consequences of hypoglycemia cannot be 
underestimated. Untreated hypoglycemia can eventually 
lead to unconsciousness and seizures, which can prove 
fatal (Figure 3).37 If blood glucose levels are not quickly 
restored, continuing hypoglycemia can lead to a decline in 
brain glucose levels, which manifests as neuroglycopenic 
symptoms (Figure 3).36,38 There is evidence to suggest that 
hypoglycemia events in children have deleterious effects 
on cognitive functioning, with successive events resulting 
in permanent neurological changes in young children.8 
Nocturnal hypoglycemia occurs in approximately 50% 
of children with diabetes, especially those aged below 
7 years.42–44 Nocturnal hypoglycemia has been attributed to 
sudden nocturnal deaths (known as “dead in bed” syndrome), 
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Figure 2 Causes identified by patients for severe hypoglycemic events (as % of group). White bar = total of all countries (type 1, 319; type 2, 320); black bar = UK (type 1, 
101; type 2, 100), grey bar = Germany (type 1, 94; type 2, 120), dotted bar = Spain (type 1, 124; type 2, 100).
Reprinted from J Med Econ, 12, M Lammert, M Hammer, BM Frier, Management of severe hypoglycaemia: cultural similarities, differences and resource consumption in three 
european countries, 269–280, copyright (2009), with permission from informa Healthcare Communications.
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Figure 3 Glycemic threshold levels for onset of acute hypoglycemia symptoms in 
nondiabetic subjects.
Reprinted  from  Hypoglycaemia  and  diabetes,  Handbook  of  Diabetes,  Oxford: 
Blackwell  Publishing  Ltd,  1st  revision,  G williams,  JC  Pickup  (editors),  copyright 
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which account for 5%–6% of all deaths among young people 
with type 1 diabetes.8,45 Contributory factors leading to noc-
turnal hypoglycemia may include the fact that early warning 
symptoms are more difficult to detect when asleep, the longer 
time intervals between meals resulting in low blood glucose 
levels, or impaired counter-regulatory mechanisms.46
Hypoglycemia symptoms are distressing and impair the 
daily functioning of people with diabetes.47 They can lead 
to sufferers feeling tired, tense and ill at ease48,49 and affect 
their quality of life.50 The Diabetes Attitudes, Wishes, and 
Needs (DAWN) study showed that 41% of people with 
diabetes (n = 5104) reported poor psychological well-being, 
with only 10% of patients reporting that they had received 
  psychological treatment for their problems.51 Moreover, 
more health care professionals (n = 3287; including primary 
care physicians, diabetes specialist physicians and nurses) felt 
able to identify and evaluate psychological needs (49%–69%) 
than had the resources to treat those needs (38%–61%).51 
  Activities of daily living such as driving become too 
  dangerous for the individual to perform and they may feel less 
able to partake in recreational and sporting activities, which 
may affect their quality of life. Elderly people with diabetes 
may also suffer fractures from falls due to hypoglycemia.52 
In addition, the fear of future severe hypoglycemia events 
also negatively influences self-management of diabetes and 
quality of glycemic control.14,53,54
Society
The consequences and treatment of hypoglycemia impose 
a significant strain on health care systems and on society in 
general.28 A recent economic analysis of the direct (health 
care resource use including the cost of follow-up training 
after an event) and indirect (work productivity) costs of 
severe hypoglycemia in 639 patients from Germany, UK, and 
Spain showed that the average treatment costs incurred due 
to severe hypoglycemia were high (€ 533 to € 691 per person 
with type 2 diabetes and € 236 to € 577 per person with type 
1 diabetes) and contributed significantly to the overall health 
care costs of diabetes in all three countries (Table 2). For 
nonhospitalized patients, telephone calls, visits to the doctor, 
blood glucose monitoring and patient education contributed 
significantly to health care costs.55 In the UK, the annual cost 
of acute treatment of hypoglycemia episodes (hospitalization 
and ambulances) was estimated at £ 15 million.56 Likewise, 
treatment of hypoglycemia episodes in type 2 diabetes 
patients in Sweden amounts to € 4.25 million per year, with 
hospitalized treatment costing approximately 10 times more 
than those treated in the community.57
Prevention strategies
The overall incidence of episodes and the likelihood of 
  suffering from a severe episode can be reduced with effective 
education directed not only at the individual with diabetes, 
but at the parents, spouse or caregiver. In fact, the require-
ment for hypoglycemia education among friends, family and 
neighbors of patients emerged as a key theme in a recent focus 
group study that was conducted to elucidate information needs 
that would facilitate future improvements in the targeting of 
education on hypoglycemia.58 As advocated and provided by 
professional diabetes organizations, such education should 
include information on the main causes of hypoglycemia 
and on the self-management of diabetes (including how to 
recognize and act on early symptoms).59 Acknowledging 
the fact that young children and their families may not be 
Table 2 Costs associated with severe hypoglycemia in three 
european countries (based on 2007 prices)
  Germany  
(€)
Spain  
(€)
UK  
(UK£)
HCP consultations
PCP office visit 7.40 15.10 32.42
PCP phone call 7.40 10.11 28.23
Diabetes specialist 19.40 52.35 112.93
Emergency HCP access costs
Ambulance 281.74 330.91 187.17
emergency physician 318.86 65.52 72.15
Taxi transfer 21.48 10.55 10.00
Private car transfer 4.10 5.00 2.60
emergency call (treatment guidance) 7.40 n/a 10.46
Hotline call (emergency) 7.40 n/a 10.46
Hospital costs
emergency room 140.61 786.91 73.00
intensive care unit n/a 1264.61 1657.37
General ward n/a 405.90 502.96
Hospitalization tariff 2517.00 n/a 612.76
Treatments
Sugar (estimate) 0.09 0.05 0.01
Sweet drinks (estimate) 0.50 0.45 0.35
Sweets, chocolate (estimate) 0.50 0.93 0.28
Oral glucose gel/paste 0.75 5.85 3.65
Glucagon (im) 27.74 21.40 11.52
Glucose (iv) 27.74 1.86 2.55
Training and other costs
education 7.40 29.66 32.42
Dietary counseling 7.40 29.66 32.42
Hypoglycemia awareness training 7.40 29.66 32.42
Psychological counseling 7.40 29.66 32.42
Leaflets, books 2.21 2.21 1.50
Blood glucose test (patient self-test) 0.50 0.89 0.29
Salary per hour 20.74 10.67 11.92
Adapted from J Med Econ, 12, M Hammer, M Lammert, SM Mejias, et al, Costs of 
managing severe hypoglycaemia in three european countries, 281–290, copyright 
(2009), with permission from informa Healthcare Communications.
Abbreviations:  HCP,  health  care  professional;  PCP,  primary  care  physician;   
n/a, not applicable; im, intramuscular; iv, intravenous.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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as accurate at recognizing the early signs and symptoms 
of low blood glucose as adult patients with diabetes, the 
2009 consensus guidelines developed by ISPAD explicitly 
stated that families of children and adolescents with diabetes 
should receive education regarding the situations when 
hypoglycemia was more likely to occur (in order to initiate 
more frequent blood glucose monitoring), including: when 
the treatment regimen is altered; in younger children; with 
lower HbA1c levels; during periods of frequent low blood 
glucose levels; when awareness of autonomic symptoms is 
reduced; during sleep; or after taking alcohol.8
One educational aspect of particular importance is the 
recommendation that individuals have an immediate source 
of glucose (for mild or moderate hypoglycemic episodes) 
and a glucagon kit (in the case of severe hypoglycemic 
episodes) always available. The American Diabetes 
Association provides simple “do/don’t” guidance for those 
assisting patients who lose consciousness during a severe 
hypoglycemic event, which can be summarized as “DO NOT 
inject insulin, provide food or fluids, or put hands in their 
mouth; DO inject glucagon and call for emergency help”.60 
Moreover, as discussed in a later section, it is imperative that 
hypoglycemia education imparted to families or caregivers 
should encompass awareness and training on the use of the 
glucagon kit in a nonhospital setting. Importantly, carers 
of adolescents may experience distress and feel unable to 
adequately undertake the administration of glucagon in 
an emergency situation. These concerns and the dearth of 
literature examining glucagon administration formed the 
basis of an investigation on the techniques used to administer 
glucagon among 136 parents of teenagers and young 
children with diabetes.19 Among this study group, 82.8% 
of whom had received initial verbal education on glucagon 
administration by a diabetes educator, handling difficulties 
(69% of parents) and inaccuracies in administering dosages 
were apparent and led the authors to conclude that training 
on glucagon administration requires “hands on” practice and 
follow-up assessment of skills.
General hypoglycemia education should also emphasize 
the importance of ensuring forward planning of meal   timing 
and timing of insulin dosing if the individual is going to be 
driving, traveling or partaking in recreational activity.   Insulin 
analogs are also increasingly being used to treat   diabetes, 
and these have a lower risk of severe hypoglycemia than 
human insulins.61 In the context of educating patients on 
preventing hypoglycemia, the Diabetes Care and Education 
group of the American Dietetic Association propose a series 
of questions that individuals should pose to themselves 
to act as a prompt: “Can my diabetes medications cause 
hypoglycemia? Have my diabetes medications changed?”; 
“Has my meal plan changed? Am I eating regular meals 
and snacks?”; “Have I been more active than usual?”; “Did 
I drink alcoholic   beverages on an empty stomach?”.59 The 
need for hypoglycemia education is undisputed, but one 
retrospective cohort study suggests potential inadequacies 
remain with respect to education on the prevention of hypo-
glycemia. In this study, a review of patient charts for emer-
gency department discharge instructions provided to patients 
hospitalized with possible hypoglycemia (64% had confirmed 
hypoglycemia) revealed that such instructions rarely included 
recommendations to avoid recurrent hypoglycemia (3% of 
cases), check blood glucose before driving (0.4%), or to 
obtain glucagon emergency kits (2%).62
Dissemination of relevant information to patients 
regarding diabetes self-management and hypoglycemia is 
increasingly undertaken in the form of various educational 
materials or media including videos, brochures, and struc-
tured teaching. Improvements in education on preventing 
hypoglycemia and how best to self-manage diabetes could 
ultimately reduce the pressure put on the emergency medi-
cal services. Indeed, interventional programs incorporating 
structured diabetes education (for example, implementation 
of a video and brochure or lessons [five 90-minute sessions 
for 5 weeks]) have achieved favorable outcomes in terms of 
reducing the incidence of severe hypoglycemia.63,64 A recent 
survey found that German and Spanish patients were much 
more likely to receive such training than those in the UK, 
which could explain why fewer patients in Germany expe-
rienced five or more episodes of severe hypoglycemia than 
those in Spain and the UK.28
Management strategies
Treatment of hypoglycemia is dependent on the duration 
and severity of the hypoglycemia episode. Mild-to-moderate 
hypoglycemia is easily self-treated with the oral intake of 
rapid-acting carbohydrates such as a glucose drink, tablets, or 
snacks.9 On the other hand, by virtue of its definition, severe 
hypoglycemia necessitates external help.
Dextrose
For patients who are unable to swallow oral glucose due 
to unconsciousness, seizures, or altered mental status, 
emergency personnel can administer a peripheral or central 
IV solution containing dextrose. Dextrose in water at a 50% 
concentration is the dose usually administered to adults, while 
a 25% concentration is usually administered to children. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Dextrose 50% and 25% are heavily necrotic due to their 
hyperosmolarity properties, which can cause tissue necrosis 
if the IV line becomes infiltrated;65 therefore, they must only 
be administered via a patent IV line.
Glucagon
As the main counter-regulatory hormone to insulin, 
glucagon is the first-line treatment for severe hypoglycemia 
in insulin-treated patients with diabetes. Unlike dextrose, 
which must be administered intravenously by a qualified 
health care professional, glucagon can be administered 
by subcutaneous (SC) or intramuscular (IM) injection by 
trained parents or caregivers. This can prevent the delay in 
commencing treatment that is otherwise experienced while 
waiting for the arrival of emergency personnel, reducing 
the need for hospitalization and providing reassurance for 
patients and their caregivers.66 The hormone is secreted 
by the pancreas, and acts to maintain glucose production 
through glycogenolysis and gluconeogenesis in the liver.67 
The pharmacokinetic and pharmacodynamic profiles of 
recombinant glucagon have been evaluated following SC and 
IM administration, with glucagon demonstrating a short half-
life (∼8–18 minutes), and maximum plasma concentrations 
achieved a few minutes after SC or IM injection.68,69
Efficacy, safety and tolerability
Substantial evidence shows that glucagon is efficacious in 
restoring blood glucose levels and consciousness (  Figure 4), 
and is safe and tolerable in treating severe hypoglyce-
mia whether injected intravenously, intramuscularly, or 
subcutaneously.70–72 While parenteral glucagon is used to treat 
patients with type 1 diabetes experiencing a hypoglycemic 
episode, IV glucose is a commonly used treatment for severe 
hypoglycemia in type 2 diabetes.9 As glucagon stimulates 
insulin secretion in addition to glycogenolysis,9 use of 
  glucagon in type 2 diabetes may be considered for those 
patients with advanced disease who are receiving intensive 
insulin therapy.27 Glucagon is not recommended for IV infu-
sion or to be used in patients on sulfonylureas;9 for those 
patients, an IV glucose bolus followed by continuous IV 
infusion is preferred until the effects of the sulfonylureas have 
worn off.27 Nausea and vomiting are sometimes reported as 
side effects of glucagon particularly with doses .1 mg, but 
such reports are rare and can occur after severe hypoglycemia 
even when glucagon is not used. The risks associated with 
glucagon use are lower than those associated with severe 
hypoglycemia, plus glucagon can lead to a faster recovery 
than calling for paramedics and waiting for them to start an 
IV line to give dextrose. There have been reports of allergic 
reactions following glucagon administration, but these have 
usually been seen when treating indications other than hypo-
glycemia and there have been no reports of adverse reactions 
suggestive of glucagon toxicity.72
Glucagon kits
The Glucagon Emergency Kit (Eli Lilly and Co, Indianapolis, 
IN) and the GlucaGen® Hypokit® (Novo Nordisk A/S, 
Bagsværd, Denmark) are the currently available glucagon 
kits administered by IM or SC injection. The glucagon 
kits comprise a brightly colored case, containing a vial of 
glucagon powder, a syringe prefilled with solvent, and text 
and graphic instructions for reconstitution and use, designed 
so that they are easy to locate and use in an emergency 
situation.
A 1 mg dose of glucagon (reconstituted in 1 mL of sterile 
water) is recommended for adults and children over 25 kg 
in weight or children aged 6 to 8 years or above and a half 
dose (0.5 mL) is recommended for children below 25 kg in 
weight or younger than 6 to 8 years of age. To administer 
the kit, the user is instructed to open the vial by breaking 
off the plastic cap, to inject the solvent into the vial con-
taining the glucagon powder, and to shake the vial until the 
reconstituted solution is clear and has no particles. They are 
then instructed to withdraw the reconstituted solution back 
into the syringe and to inject into the unconscious person’s 
leg or abdomen immediately. The unconscious person should 
be rolled onto their side in case of vomiting during recovery. 
If the patient does not respond immediately after receiving 
glucagon, medical help should be sought and IV glucose 
administered as soon as possible.5,9 If the patient does respond 
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Figure 4 Changes in blood glucose levels before and after the administration of 
1 mg biosynthetic glucagon. 
Reprinted from Diabetes Res Clin Pract, 19, M Namba, T Hanafusa, N Kono, et al, Clinical 
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to glucagon by regaining consciousness, it is advised that they 
are assessed in an emergency room due to depletion of their 
glycogen stores, which may lead to rebound hypoglycemia.27 
For more information on the Glucagon Emergency Kit 
and the GlucaGen® Hypokit®, see http://www.humalog.
com/humalog-diabetes-and-insulin/glucagon-tutorial.jsp 
and http://www.novonordisk.com/diabetes/public/hypokit/
hypokit/product-information.asp, respectively.
Continuous education on the use of glucagon kits is 
highly recommended for caregivers who should always be 
aware of the location of the kit, should store the kit at room 
temperature, and should always ensure that the expiration 
date has not passed.19 Training for family, caregivers and 
friends on how to use glucagon kits is vital to ensure accurate 
administration of glucagon19 and to reassure them that they 
cannot injure the patient by administering glucagon. It may 
be of benefit for family and caregivers to practice giving the 
injections with saline so that they are more confident if a 
real emergency happens. They should also be advised on the 
importance of avoiding any delay in treating the patient so 
that blood glucose levels can be raised as soon as possible.
Conclusion
Glucagon is a safe and reliable alternative to IV glucose 
infusion70 and is the only treatment for severe hypoglycemia 
events that can be used in nonhospital environments. 
However, to date, glucagon remains underappreciated and 
underused19 despite its documented benefits. Underutilization 
of glucagon may partly be attributed to a lack of adequate 
education and training or may be a result of unsubstantiated 
fears of harming the patient or of the side effects.19 The 
same misconceptions are seen in schools, clubs and other 
childcare facilities leading to a further reluctance to inject 
glucagon. This situation is unfortunate because it means that 
the incidence of severe hypoglycemia will probably rise due 
to the increasing number of people with diabetes and the shift 
to more intensive insulin regimens.27
So how can management of severe hypoglycemia be 
improved? With the cooperation of patients, families, and 
health care providers, better information and continued edu-
cation and more frequent use of glucagon, it may be possible 
to achieve short-term benefits in managing hypoglycemia 
episodes, long-term improvements in glycemic control, as 
well as reduced incidence of late diabetes complications, 
and fewer hospital admissions in diabetes patients.27 The 
introduction of training on the use of glucagon kits for school 
nurses, sports coaches and others who work with children 
would be worthwhile as it may lead to the same benefits.
The use of glucagon also has the potential to confer 
economic advantages and to free up health care resources 
by reducing the number of patients who have to be admitted 
to hospital with severe hypoglycemia. More importantly, 
glucagon treatment can ease the anxiety and worry that 
accompanies a severe hypoglycemia event. Since glucagon 
kits are easy to use and show minimal risk in terms of the 
effect of the drug on the patient and the procedure of inject-
ing, there is a strong argument for more frequent use of these 
kits in the treatment of severe hypoglycemia.
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